Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)DivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Roivant Sciences (ROIV) Cash from Financing Activities (2020 - 2025)

Roivant Sciences (ROIV) has disclosed Cash from Financing Activities for 6 consecutive years, with $328.2 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash from Financing Activities rose 131.48% year-over-year to $328.2 million, compared with a TTM value of -$839.6 million through Dec 2025, up 38.28%, and an annual FY2025 reading of -$1.2 billion, down 390.87% over the prior year.
  • Cash from Financing Activities was $328.2 million for Q4 2025 at Roivant Sciences, up from $62.6 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $452.0 million in Q4 2023 and bottomed at -$1.0 billion in Q4 2024.
  • Average Cash from Financing Activities over 5 years is $6.8 million, with a median of $62.6 million recorded in 2025.
  • The sharpest move saw Cash from Financing Activities surged 2931.66% in 2023, then crashed 8935.31% in 2024.
  • Year by year, Cash from Financing Activities stood at $305.7 million in 2021, then dropped by 5.43% to $289.1 million in 2022, then surged by 56.33% to $452.0 million in 2023, then plummeted by 330.68% to -$1.0 billion in 2024, then surged by 131.48% to $328.2 million in 2025.
  • Business Quant data shows Cash from Financing Activities for ROIV at $328.2 million in Q4 2025, $62.6 million in Q3 2025, and -$187.8 million in Q2 2025.